Ventus Therapeutics Releases Findings of Phase 1 Study for VENT-02, an Innovative Oral Brain-Targeting NLRP3 Inhibitor.

After a drug clinical trial is approved, it must commence within three years from the date of approval.

Press Announcement: Latest 48-week stage 2 findings on frexalimab indicate promising consistent effectiveness in treating multiple sclerosis.

April 19th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Alvotech and Teva have received FDA clearance in the U.S. for their product SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab).

Comparing Synthetic and Recombinant Peptide Production: Processes, Applications, Costs, and Scalability.

Eloxx Pharmaceuticals, Inc. announced recent developments in their programs for ELX-02 and ZKN-013, highlighting the Orphan Drug Designation awarded to ELX-02.

On April 5, 2024, the 2024 AACR present the updated data from a Phase 2 expansion cohort for patients (pts) with advanced NSCLC.

In the TOPAZ-1 Phase III trial, the combination of Imfinzi and chemotherapy increased the three-year overall survival rate by twofold in patients with advanced biliary tract cancer.

Toxoids and antitoxins are distinct biological products used to prevent and treat toxin-related bacterial diseases, differing in origin, preparation, and function.

Neurona Therapeutics Reports Encouraging Results from Its NRTX-1001 Cell Therapy Study in Adults Suffering from Drug-resistant Focal Epilepsy at the 2024 AAN Annual Meeting.

On April 5, 2024, the final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors were reported in 2024 AACR.